This site is for UK Healthcare Professionals Only
Adverse event reporting information can be found at the bottom of this page
Discover LYNPARZA®, the first PARP inhibitor approved in the UK for the three following types of cancer:
Learn more by selecting a therapeutic indication below
Lynparza tablets are indicated as monotherapy for:1
The maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
The maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.
Lynparza in combination with bevacizumab is indicated for:1
The maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.
LYNPARZA is indicated as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy.
LYNPARZA is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.1
LYNPARZA tablets are indicated as monotherapy for:1
The treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent
LYNPARZA tablets are indicated in combination with abiraterone and prednisone or prednisolone for:1
The treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated
For full details of the Lynparza indications please refer to the Summary of Product Characteristics.1
Please refer to the Summary of Product Characteristics before prescribing to help minimise the risks associated with the use of Lynparza.1
Reference:
- Lynparza (olaparib) Tablets Summary of Product Characteristics.